Amplifyer Bio Analysis: $7M Raised
What is Amplifyer Bio?
Amplifyer Bio develops priming agents that enhance cfDNA levels in blood for cancer diagnostics. The technology combines research from MIT and the Broad Institute to improve genomic information quality. The company's first program targets increasing cfDNA for better clinical outcomes in oncology.
Location
Cambridge, United States
Employees
1-10
Founded
2023
Funding Status
Seed
Product Features & Capabilities
- Priming agents to increase cfDNA in blood
- Enhances genomic information quality for cancer diagnostics
- Improves clinical outcomes in oncology
Use Cases
Improve cancer diagnostics by increasing cfDNA in blood; Enhance genomic information quality for oncology patients; Improve clinical outcomes in cancer care
Other Considerations
Founded by Dr. Sangeeta Bhatia, Dr. Chris Love, and Dr. Viktor Adalsteinsson; Research published in Science; Presented at leading international conferences; MIT and Broad Institute collaboration
See something that needs updating? Suggest edits to this profile.